Osteoarthritis(OA)is a common chronic degenerative disease,which can lead to multiple tissue injuries such as articular cartilage,synovial membrane and subchondral bone.At present,the pathogenesis of the disease is not fully understood.Studies have found that Matrix metalloproteinase(MMPs)is related to the pathogenesis of the disease,especially MMP13,which expression level in the body is closely related to OA.In recent years,in view of the role of MMP13 in the occurrence and development of this disease,there has been some progress in the treatment of OA by targeting MMP13.Compared with broad-spectrum MMPs inhibitors,selective MMP13 inhibitors have some advantages such as strong selectivity,low toxicity and high efficacy,but frequent administration is required to maintain the effective concentration of the drug in vivo;injection of small interfering RNA that is selectively complementary to MMP13 mRNA into the joint cavity can effectively reduce the production of MMP13 protein and inhibit the expression of various inflammatory factors in vivo,and a single injection can maintain the drug effect for a long time;the use of CRISPR-Cas9 gene editing technology to target the ablation of MMP13 gene to weaken the degradation of chondrocyte extracellular matrix protein in the treatment of OA has good effects on animal models both in vivo and in vitro,but the long-term safety of this technology in human beings has also triggered people's thinking.Targeted MMP13 treatment of OA is an important research direction in the medical field and scientific research field,and the combination of more advanced cutting-edge biomedical technologies in the future will provide a new strategy for exploring the treatment of OA.
维普
万方数据